Sionna Therapeutics, Inc. (NASDAQ:SION) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $53.2222.

Several analysts recently commented on the company. Stifel Nicolaus boosted their price target on Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, May 18th. JonesTrading boosted their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. BTIG Research restated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th.

Sionna Therapeutics Stock Performance

Shares of SION opened at $42.97 on Tuesday. Sionna Therapeutics has a one year low of $15.10 and a one year high of $48.44. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -22.26 and a beta of 1.30. The stock has a 50 day moving average price of $39.80 and a 200 day moving average price of $39.47.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). On average, analysts predict that Sionna Therapeutics will post -2.57 earnings per share for the current year.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,717,962 shares of company stock valued at $77,571,889. 5.10% of the stock is owned by company insiders.

Institutional Trading of Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics during the 4th quarter worth $36,000. Russell Investments Group Ltd. purchased a new position in shares of Sionna Therapeutics during the 3rd quarter worth $30,000. Balyasny Asset Management L.P. purchased a new position in shares of Sionna Therapeutics during the 4th quarter worth $58,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics during the 2nd quarter worth $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Sionna Therapeutics during the 4th quarter worth $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.